AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05527067 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Neuropsychological assessment, brain MRI, electroencephalogram and biomarker datas will be collected
Study NCT05999084 — intervention group
Intervention type: DRUG
Intervention: Anti-amyloid Monoclonal Antibodies (mAbs)
Description: Infusions of lecanemab occur every 2-weeks as indicated in the FDA labeling. After 18 months of treatment, an amyloid positron emission tomography (PET) scan with FDA-approved radiotracer is performed to confirm clearance of amyloid pathology. It is anticipated that most individuals treated with lecanemab for 18 months will no longer have positive amyloid PET scans. In those instances where persistent amyloid pathology is seen, every 2-week treatment with lecanemab will be continued for an additional 6 months with repeat amyloid PET scan until amyloid clearance is achieved. If an individual has progressed to moderate or severe stages of AD dementia during the initial 18 months of treatment and amyloid PET shows failure to clear amyloid pathology, treatment will be terminated. Dosing frequency after 18 months (or after amyloid clearance) remains unclear and will need to be determined with additional evidence development.
Study NCT05999084 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Standard of Care
Description: The standard of care, other than treatment with anti-amyloid mAbs, provided at the study clinics.
Study NCT05347693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (SZC)
Description: White to grey crystalline powder for oral suspension in 5 g sachets. Each sachet will be labeled in accordance with Good Manufacturing Practice Annex 13 and per country regulatory requirement.~Label text will be translated into local language.
Study NCT05347693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local standard of care
Description: Local SoC in the country to be used as per local label
Study NCT06445556 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NatureUplift
Description: a culturally tailored, nature-based program offered at the TRPD. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing). Following week 12, participant dyads who were randomized to the NatureUplift intervention (i.e., delayed intervention arm) will receive access to 4 additional weeks of the NatureUplift+Active intervention.
Study NCT06445556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NatureUplift+Active
Description: NatureUplift plus a supplementary walking/hiking educational component. treatment condition will have a duration of 12 weeks, with 60 min/week of nature-based, light-intensity activities (e.g., forest bathing) prescribed during the NatureUplift condition and an additional 60 min/week of supplementary moderate- intensity activities (e.g., walking and hiking) prescribed during the NatureUplift+Active condition. Those who were randomized to the NatureUplift+Active intervention will continue to receive access to 4 additional weeks of the NatureUplift+Active intervention.
Study NCT02137525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 6 mg
Description: Intravenous infusion - delivering morphine 6 mg
Study NCT02137525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 µg
Description: Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
Study NCT02137525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 200 µg
Description: Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
Study NCT02137525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 400 µg
Description: Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
Study NCT02137525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Sublingual Spray
Description: Matching sublingual spray - single unit delivering 0 µg fentanyl
Study NCT02137525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Matching intravenous infusion - delivering 0 mg morphine
Study NCT05658367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with sesame- lavender oil mixed
Description: After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame- lavender oil mixed for 15 minutes with classical massage manipulations.
Study NCT05658367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy massage with sesame oil
Description: After the surgery, 3 hours after the painkiller application, the patients will massage their arms with sesame oil for 15 minutes with classical massage manipulations.
Study NCT05658367 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Massage with parraffin oil
Description: After the surgery, 3 hours after the painkiller application, the patients will massage their arms with paraffin oil for 15 minutes with classical massage manipulations.
Study NCT05612386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study NCT05822596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-based interactive games experimental group intervention
Description: The program consists of 24 facilitated sessions and, depending on the capability of the participants, the availability of mobile devices and the service setting, 0 - 84 non-facilitated sessions.~In 30-minute facilitated session, a program facilitator will lead 1-8 participants in playing the tablet-based interactive games and helpers (e.g., health workers, program workers, and volunteers) will assist the program facilitator in running the sessions. The games may be played individually or together with other participants. In non-facilitated sessions, the participants can play cognitive games depending on the capability of themselves and at their own pace for 10 - 30 minutes
Study NCT05420428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: supraglottic airway device
Description: under general anesthesia, patients received supraglottic airway device
Study NCT05420428 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: endotracheal intubation
Description: under general anesthesia, patients received endotracheal intubation
Study NCT05521854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare app (app-based contingency management)
Description: Participants will receive financial incentives for submitting randomly generated drug-negative saliva tests across the intervention period.
Study NCT05521854 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: Participants get access to the DynamiCare app but will not be provided with financial incentives.
Study NCT05059379 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Entire supraclavicular lymph node radiotherapy
Description: Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.
Study NCT05059379 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Medial supraclavicular lymph node radiotherapy
Description: Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.
Study NCT04436315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motor-cognitive training device
Description: Motor-cognitive training device
Study NCT04436315 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Active control condition
Description: Physical activity program
Study NCT05847179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progerinin
Description: This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.~. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.
Study NCT06075420 — intervention group
Intervention type: DEVICE
Intervention: Genoss DES stent
Description: The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Study NCT05547243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
Description: 50μg/dose
Study NCT05547243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA Vaccine, Bivalent High dose
Description: 100μg/dose
Study NCT05721742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtually administered dietitian consults for IBS patients.
Description: Participants will receive virtual one on one consults with a dietitian who has training in the dietary management of IBS.
Study NCT05721742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IBS Group Online Session
Description: IBS online group session run by Happy Bellies Nutrition
Study NCT05978544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab
Description: Patients to be treated with Itolizumab.
Study NCT06285851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FeSC
Description: Supplement
Study NCT06075446 — intervention group
Intervention type: BEHAVIORAL
Intervention: ACT Raising Safe Kids
Description: American Psychological Association ACT Raising Safe Kids
Study NCT05547243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT05114655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbaceous Essential Oil Blend
Description: Participants are given a diluted proprietary oil blend of aromatic extracts from resins, bark, and flowers to apply three times daily for the purposes of inhalation.
Study NCT04074304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: I-HoME
Description: A multi-component technology-based care intervention.
Study NCT05114655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Citrus Essential Oil Blend
Description: Participants are given a diluted proprietary oil blend of aromatic extracts from citrus peel, and flowers to apply three times daily for the purposes of inhalation.
Study NCT05114655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inert Oil
Description: Participants are given an inert vegetable based oil blend to apply three times daily for the purposes of inhalation.
Study NCT05158296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultevursen
Description: RNA antisense oligonucleotide for intravitreal injection
Study NCT05158296 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure
Description: Sham-procedure (no experimental drug administered)
Study NCT05037968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagnetOs Flex Matrix
Description: Procedure: Instrumented Posterolateral Lumbar Fusion
Study NCT05037968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trinity Elite
Description: Procedure: Instrumented Posterolateral Lumbar Fusion
Study NCT00269802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate HCl
Study NCT00269802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin
Study NCT00269802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04728048 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dural puncture epidural
Description: already described
Study NCT04728048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard epidural
Description: already described
Study NCT05666219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline Injection
Description: Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.
Study NCT05093049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Renuvion APR System
Description: The Renuvion APR Handpiece (K191542) is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. The Renuvion APR Handpiece is compatible with the Electrosurgical Generators BVX-200H/P (K170188), and APYX-JS3/RS3 (K192867) owned by Apyx Medical that are indicated for delivery of radiofrequency energy and/or helium gas plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures.
Study NCT05093049 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gynecomastia Correction Surgery
Description: Gynecomastia correction surgery as per the investigators standard treatment of care utilizing liposuction.
Study NCT06380699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QHRD106 Injection
Description: PEG-tissue kallikrein-1
Study NCT06380699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Urinary Kallidinogenase
Description: tissue kallikrein-1
Study NCT06380699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04858698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound / Echocardiography
Description: Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
Study NCT04858698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound / Echocardiography
Description: Ultrasound will be used to guide vascular access and to place a lead into the right ventricle.
Study NCT06148220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT imaging
Description: Intravenous injection of 3.7 MBq \[0.1 mCi\]/kg of \[18F\]RCCB6 or \[68Ga\]Ga-NOTA-RCCB6 in a single dose
Study NCT05081869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: An online yoga-based exercise program will be applied for 16 sessions in individuals' own environments. The exercise program will consist of stretching, mobilization, stabilization, strengthening and relaxation exercises.
Study NCT05081869 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education Program
Description: There will be video training on the subject for both groups.
Study NCT05081869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Program
Description: There will be video training on the subject for both groups.
Study NCT06081764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Doing Otago Exercise Program, which lasting 3 days a week and an average of 30 minutes per day under the supervision of a physiotherapist. Also doing walking exercise for 30 minutes a day, 2 days a week for total of 12 weeks.
Study NCT05369715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise
Study NCT05906082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette cessation text-messaging intervention
Description: This is the intervention for e-cigarette cessation using text messages targeting young adults in rural areas.
Study NCT05752799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Free Anaesthesia
Description: * 40 mg/kg magnesium sulfate in 100 ml N/S infusion~* 0.4 mcg/kg dexmedetomidine, max total dose 50mcg in 50 ml N/S infusion~* 0.3 mg/kg ketamine in 10 ml volume~* 0.2 ml/kg of the Multimix regimen in 100 ml N/S infusion as a bolus (The Multimix regimen consists of 50mcg dexmedetomidine, 500 mg lidocaine and 50mg ketamine).~* 0.2 ml/kg/h of the Multimix regimen in 100 ml N/S infusion as a continuous infusion. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value > 25 or elevation of Heart Rate and/or Blood Pressure >20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Study NCT05752799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based anesthesia
Description: * 2 mcg/kg fentanyl in 10 ml volume~* 0.2 mL/kg/h remifentanil infusion~* 0.1 mg/kg morphine. Except for standard analgesic strategies, both groups will receive fentanyl as a rescue dose (1mcg/kg) based on a nociceptive level value > 25 or elevation of Heart Rate and/or Blood Pressure >20%.~Placebo infusions of normal saline will be prepared to enable blinding.
Study NCT05347758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535
Description: Drug: HRS-7535
Study NCT05347758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study NCT06361901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenicog;language rehabilitation program
Description: This program is an AI-based computerized cognitive and language training program.
Study NCT06361901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional language rehabilitation
Description: Conventional language rahabilitation therapy will apply for all participants with speech impairement
Study NCT06361901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional language rehabilitation
Description: Conventional language rahabilitation therapy will apply for all participants with speech impairement
Study NCT05776953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV Ketorolac for pain
Study NCT05906082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care control using standard national resources
Description: This is the standard care with national resources from smokefree.gov.
Study NCT06530251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Following a predefined dose and date.
Study NCT06530251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Following a predefined dose and date.
Study NCT06530251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK127
Description: Following a predefined dose and date.
Study NCT06530251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK130
Description: Following a predefined dose and date.
Study NCT06530251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab Injection
Description: Following the local label direction.
Study NCT06530251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab biosimilar
Description: Following the local label direction.
Study NCT06244550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganwei
Description: Capsules
Study NCT06244550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablets
Study NCT06244550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules
Study NCT06244550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching capsules
Study NCT05865496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 611
Description: 611 subcutaneous (SC) injection.
Study NCT05865496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection.
Study NCT05882110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cultured autologous epidermal cell membrane
Description: The cultured autologous epidermal cell membrane is made from the patient's autologous epidermal cells by in vitro rapid expansion and culture technology, which has good biocompatibility, non-toxic, non-teratogenic, can reduce the skin area cut by traditional autologous skin grafting methods, and has high proliferative activity to promote wound repair and regeneration.
Study NCT05531279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF group A(q7d):6mg d1,8,subcutaneously injected; PEG-rhG-CSF group B(q10d):6mg d1,11,subcutaneously injected; RhG-CSF group(short-acting ): 480ug d1-14(daily for 14days),subcutaneously injected.
Study NCT04715516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alcohol brief intervention
Description: Nested within the lifestyle health promotion provided in both conditions, participants randomised to the experimental condition will receive an alcohol brief intervention. The strong evidence-base for alcohol brief intervention, amplified by Co-Investigators' Smith and Bragge's (BehaviourWorks) approaches to applied behaviour change, has provided the framework for the development of the alcohol brief intervention used in this study. This intervention comprises personalised feedback on alcohol consumption levels, comparison to gender/age drinking norms, and information and behaviour-change content regarding alcohol consumption (i.e. negative-framed messaging around alcohol risks and harms, positive-framed messaging on the health benefits of reducing alcohol intake, alcohol harm reduction strategies).
Study NCT04715516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle health promotion
Description: Lifestyle health promotion specific to physical activity and maintaining a healthy weight, developed to be relevant to women attending breast screening services, will be provided.